From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 14, 2012, Pages 1925-1933

  Alberti, C ^a  

^a LD of Surgical Semeiotics   (Italy)

Author keywords

Cancer xenografts; MRI; Nanotechnology; Nuclear imaging; Optical imaging; SAIFS; Tissue engineered models

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; FLUORESCENCE IMAGING; GENE THERAPY; HUMAN; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NEOPLASMS; OPTICAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874029226     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. DE SAINT-HUBERT M, BAUWENS M, VERBRUGGEN A, MOTTAGHY FM. Apoptosis imaging to monitor cancer therapy: the read to fast treatment evaluation? Curr Pharm Biotechnol 2012; 13: 571-583.
2. KURIHARA H, HONDA N, KONO Y., ARAY Y. Radiolabelled agents for PET imaging of tumor hypoxia. Curr Med Chem 2012; 19: 3282-3289.
3. GRASSI R, LAGALLA R, ROTONDO A. Genomics, proteomics, MEMS and SAIF: which role for diagnostic imaging? Radiol Med 2008; 113: 775-778.
4. GIORGETTI A, VOLTERRANI D, MARIANI G. Clinical oncological applications of PET using Fluorine-18-Fluoro-2-deoxy-D-glucose. Radiol Med 2002; 103: 293-318.
5. JANA S, BLAUFOX MD Nuclear medicine studies of the prostate, testes and bladder. Semin Nucl Med 2006; 36: 51-72.
6. LANGSTEGER W, HEINISCH M, FOGELMAN I. The role of fluorodeoxyglucose, 18F-dehydroxyphenilalanine, 18F-choline and 18F-fluoride in bone imaging with enphasis on prostate and breast. Semin Nucl Med 2006; 36: 73-92.
7. PELOSI E, ARENA V, SKANJETI A., PIRRO V, DOUROUKAS A, PUPI A., MANCINI M. Role of whole-body 18Fcholine PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113: 895-904.
8. OYEN WJG, WITJES JA, CORSTENS FHM. Nuclear medicine techniques for diagnosis and therapy of prostate carcinoma. Eur Urol 2001; 40: 294-299.
9. Brush JP. Positron emission tomography in urological malignancies. Curr Opin Urol 2001; 11: 175-179.
10. VEES H, BUCHEGGERT F, ALBRECHT S., KHAN H, HUSARIK D, ZAIDIT H., SOLOVIEV D, HANY TF, MIRABELL R. 18F-choline and/or 11C-acetate PET: detection of residual or progressive subclinical disease at very low PSA values (<1 ng/mL) after radical prostatectomy. BJU Internat 2007; 99: 1415-1420.
11. PICCHIO M, LANDONI C, MESSA C., GIANOLLI L, MATARRESE M, DE COBELLI F, MASCHIO AD, FAZIO F. Positive 11C-choline and negative 18F-FDG with PET in recurrence of prostate cancer. AJR 2002; 179: 482-484.
12. RINNAB L, BLUMSTEIN NM, MOTTAGHY F.M., HAUTMANN RE, KÜFER R, HOHL K., RESKE SN 11-Choline PET/CT and transrectal ultrasonography for staging localized prostate cancer. BJU Internat 2007; 99: 1421-1426.
13. Hain SF, Maisey MN Positron emission tomography for urological tumours. BJU Internat 2003; 92: 159-164.
14. TOTH G, LENGYEL Z, BALKAY L., SALAH MA, TRON L, TOTH C. Detection of prostate cancer with 11C-methionine PET. J Urol 2005; 173: 66-69.
15. GIORGETTI A, RUFINI V, CALCAGNI M.L., BAUM R. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228-247.
16. GRASSI R, CAVALIERE C, COZZOLINO S., MANSI L, CIRILLO S, TEDESCHI G., FRANCHI R, RUSSO P, CORNACCHIA S., ROTONDO A. Small animal imaging facilities: new perspectives for the radiologist. Radiol Med 2009; 114: 152-167.
17. KONG FL, YANG DJ Amino-acid transporter-targeted radiotracers for molecular imaging in oncology. Curr Med Chem 2012; 19: 3271-3281.
18. ELLIS RJ, ZHOU EH, FU P, KAMINSKY D.A., SODEE DB, FAULHABER PF, BODNER D, RESNICK MI SPECT with Capromab pentetide plus CT image set co-registration indipendently predicts biochemical failure. Urol 2008; 179: 1768-1774.
19. KAHN D, WILLIAMS RD, HASEMAN M.K., REED NL, MILLER SJ, GERSTBREIN J. Radioimmunoscintigraphy with In-111-labeled Capromab pentetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16: 284-289.
20. 111In-Capromab radioim-munoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21: 1715-1721.
21. GOLMAN K, OLSSON LE, AXELESSON O, MANSSON S., KARLSSON M, PETERSSON JS Molecular imaging using hyperpolarized 13C. Br J Radiol 2003; 76: S118-127.
22. ALBERS MJ, BOK R, CHEN A P, CUNNINGHAM CH, ZIERHUT M.L., ZHANG V Y, KOHLER SJ TROPP J, HURD RE, YEN Y F, NELSON SJ, VIGNERON DB, KURHANEWI CZ. Hyperpolarized 13C-lactate, pyruvate and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008; 68: 8607-8615.
23. GALLAGHER FA, KETTUHEN MI, DAY S.E., HU DE, ARDENKJAER-LARSEN JH, ZANDT R, JENSEN P.R., KARLSSON M., GOLMAN K, LERCHE MH, BRINDLE KM Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008; 453: 940-943.
24. CASCIANI E, POLETTINI E, BERTINI L., EMILIOZZI P, AMINI M, PANSADORO V., GUALDI GF Prostate cancer: evalutation with endorectal MR imaging and 3D-proton spectroscopic imaging. Radiol Med 2004; 108: 530-541.
25. POLASEK M, FUCHS BC, UPPAL R, SCHÜHLE DT, ALFORD J.K., LOVING GS, YAMADA S, WEI L, LAUWERS G Y, GUIMARAES AR, TANABE K.K., CARAVAN P. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012; 57: 549-555.
26. TERRENO E, DELLI CASTELLI D, CABELLA C, Dastrù W, SANINO A, STANCANELLO J, TEI L, AIME S. Paramagnetic liposomes as innovative contrast agents for MR molecular imaging applications. Chem Biodivers 2008; 5: 1901-1912.
27. FRASCIONE D, DIWOKY C, ALMER G., OPRIESSNIG P, VONACH C, GRADAUER K., LETTINGER G, MANGGE H, STOLBERGER R., PRASS R. Ultrasmall superparamagnetic iron-oxide (USPIO)-based liposomes as MR probes. Int J Nanomedicine 2012; 7: 2349-2359.
28. TERRENO E, DASTRÙ E, DELLI CASTELLI D, GIANOLIO E, GENINATTI CRICH S, LONGO D, AIME S. Advances in metalbased probes for MR molecular imaging applications. Curr Med Chem 2010; 17: 3684-3700.
29. ONOZATO ML, ANDREWS PM, LI Q, JIANG J., CABLE A, CHEN Y. Optical coherence tomography of human kidney. J Urol 2010; 183: 2090-2094.
30. ABBANDONATO G, SIGNORE G, Nifosì R, VOLIANI V, BIZZARRI R, BELTRAM F. Cis-trans photoisomerization properties of GFP chromophore analogs. Eur Biophys J 2011; 40: 1205-1214.
31. CHEN K, XIE J, CHEN X. RDG-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 2009; 8: 65-73.
32. OHNISHI S, LOMNES SJ, LAURENCE R.G., GAGBASHIAN A., MARIANI G, FRANGIONI J V. Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging 2005; 4: 172-181.
33. KWON S, KE S, HOUSTON J P, WANG W, WU Q., LI C, SEVICK-MURACA EM. Imaging dose-dependent pharmacokinetics of RDG-fluorescent dye conjugate targeted to αVβ3 receptor expressed in Kaposi's sarcoma. Mol Imaging 2005; 4: 75-87.
34. KOVAR JL, VOLCHECK W, SEVICK-MURACA EM, SIMPSON M.A., OLIVE DM Characterization and performance of near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem 2009; 384: 254-262.
35. ADAMS KE, KE S, KWON S., LIANG F, FAN Z, LU Y., HIRSCHI K, MAWAD ME, BARRY M.A., SEVICK-MURACA EM. Comparison of visible and near-infrared wavelenght-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007; 12: 024017.
36. LAXMAN B, HALL DE, BHOJANI M.S., HAMSTRA DA, CHENEVERT TL, ROSS BD, REHEMTULLA A. Noninvasive real-time imaging of apoptosis. PNAS 2002; 99: 16551-16555.
37. WANG S, LI W, ZUE Z., LU Y, NARSINH K, FAN W., LI X, BU Q, WANG F., LIANG J, WU K, CAO F. Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog 2012; (in press)
38. FILLAT C, CARRIO M, CASCENTE A., SANGRO B. Suicide gene therapy mediated by H.S.V. thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
39. RUSSELL SJ, PENG K-W. Gene therapy. Mayo Clin Proc 2003; 78: 1370-1383.
40. WEISSLEDER R. Molecular imaging: exploring the next frontier. Radiology 1999; 212: 609-614.
41. BANGMA CH, MONGIAT P, KRAAIJ R., SCHENK-BRAAT E. Gene therapy in urology: strategies to translate theory into practice. BJU Internat 2005; 96: 1163-1170.
42. MALMBERG J, SANDSTRÖM M, WESTER K., TOLMACHEV V, ORLOVA A. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminate prostate cancer in mice bearing prostate cancer xenografts. Nucl Med Biol 2011; 38: 1093-1102.
43. KATAOKA M, YAMAGUCHI Y, MORIYA Y., SAWADA N, YASUNO H, KONDOH K., EVANS DB, MORI K, HAYASHI S. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Oncol Rep 2012; 27: 303-310.
44. Zhou W, Zhu H, Chen W., Hu X, Pang X, Zhang X., Huang X, Fang B, He C. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer Gene Ther 2011; 18: 336-345.
45. SERWER LP, NOBLE CO, MICHAUD K, DRUMMOND D.C., KIRPOTIN DB, OZAWA T, PRADOS MD, PARK J.W., JAMES CD Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic gliobastoma xenografts. Neuro Oncol 2011; 13: 1288-1295.
46. ZHANG S. Fabrication of novel biomaterial through molecular self-assembly. Nature Biotechnol 2009; 21: 1171-1178.
47. HUTMACHER DW, LOESSNER D, RIZZI S., KAPLAN DL, MOONEY DJ, CLEMENTS JA Can tissue engineering concepts advance tumor biology research? Trends Biotechnol 2010; 28: 125-133.
48. SCHANZ J, PUSCH J, HANSMANN J., WALLES H. Vascularized human tissue models: a new approach for the refinement of biomedical research. J Biotechnol 2010; 148: 56-63.
49. FERRARI M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-171.
50. SINGH AK, HAHN MA, GUTWEIN L.G., RULE MC, KNAPIK JA, MOUDGIL BM, GROBMYER S.R., BROWN SC Multidye theranostic nanoparticle platform for bioimaging and cancer therapy. Int J Nanomedicine 2012; 7: 2739-2750.
51. YAKU H, FUJIMOTO T, MURASHIMA T. MIYOSHI D, SUGIMOTO N. Phthalocyanines: a new class of Gquadruplex-ligands with many potential applications. Chem Commun 2012; 48: 6203-6216.
52. YANG K, HU L, MA X., YE S, CHENG L, SHI X. LI C, LI Y, LIU Z. Multimodal imaging-guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater 2012; 24: 1868-1872.
53. Yang X, Liu X, Liu Z., Pu F, Ren J, Qu X. Near-Infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater 2012; 24: 2890-2895.
54. Ren T, Liu Q, Lu H., Liu H, Zhang X, Du J. Multifunctional polymer vesicles for ultrasensitive MRI and drug delivery. J Mater Chem 2012; 22: 12329-12338.
55. BAUM R.P., KULKARNI HR Theranostic: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy. The Bad Berka experience. Theranostics 2012; 2: 437-447.
56. MELANCON M.P., STAFFORD RJ, LI C. Challenges to effective cancer nanotheranostics. J Control Release 2012; 164: 177-182.
57. KUMAR R, KULKARNI A, NAGESHA D.K., SRIDHAR S. In vitro evaluation of theranostic polymer micelles for imaging and drug delivery in cancer. Theranostics 2012; 2: 714-722.
58. MAYOR JL, MEADE TJ Bioresponsive, cell-penetrating and multimeric MR contrast agents. Acc Chem Res 2009; 42: 893-903.
59. TEMPANI CM, MCNEIL BJ Advance in biomedical imaging. JAMA 2001; 285: 562-567.
60. MILLER AD. Towards technologies for nucleic acid therapy. Tumori 2008; 94: 234-245.
61. BU L, XIE J, CHEN K., HUANG J, AGUILAR Z P, WANG A, SUN K.W., CHUA MS, SO S, CHENG Z, EDEN H.S., SHEN B., CHEN X. Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol Imaging 2012; 7: 363-372.
62. HAMAD-SCHIFFERLI K., SCHWARTZ J. SANTOS A, ZHANG S, JACOBSON J. Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna. Nature 2002; 415: 152-155.
63. YANG J. Mens-based probe recording technology. J Nanosci Nanotechnol 2007; 7: 181-192.
64. JOKERST J.V., GAMBHIR SS Molecular imaging and theranostic nanoparticles. Acc Chem Res 2011; 44: 1050-1060.
65. Li Y, Li Z, Wang X., Liu F, Cheng Y, Zhang B., Shi D. In vivo cancer targeting and imaging-guided surgery with NIR-emitting quantum dot bioconjugates. Theranostics 2012; 2: 769-776.